{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:25:44Z","timestamp":1783574744425,"version":"3.55.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008061","name":"Fundaci\u00f3n Mutua Madrile\u00f1a","doi-asserted-by":"crossref","award":["08\/FMMA"],"award-info":[{"award-number":["08\/FMMA"]}],"id":[{"id":"10.13039\/100008061","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Fondo de Investigaciones Sanitarias and ISCIII\/Fondos FEDER","award":["PI10\/0173"],"award-info":[{"award-number":["PI10\/0173"]}]},{"name":"Fondo de Investigaciones Sanitarias and ISCIII\/Fondos FEDER","award":["PI14\/00450"],"award-info":[{"award-number":["PI14\/00450"]}]},{"name":"Fondo de Investigaciones Sanitarias and ISCIII\/Fondos FEDER","award":["PIE15\/00028"],"award-info":[{"award-number":["PIE15\/00028"]}]},{"name":"Fondo de Investigaciones Sanitarias and ISCIII\/Fondos FEDER","award":["RD06\/0020\/0101"],"award-info":[{"award-number":["RD06\/0020\/0101"]}]},{"name":"Fondo de Investigaciones Sanitarias and ISCIII\/Fondos FEDER","award":["RD12\/0036\/0071"],"award-info":[{"award-number":["RD12\/0036\/0071"]}]},{"name":"Fondo de Investigaciones Sanitarias and ISCIII\/Fondos FEDER","award":["EC07\/90065"],"award-info":[{"award-number":["EC07\/90065"]}]},{"DOI":"10.13039\/501100003030","name":"AGAUR","doi-asserted-by":"crossref","award":["2009-SGR-168"],"award-info":[{"award-number":["2009-SGR-168"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003030","name":"AGAUR","doi-asserted-by":"crossref","award":["2014-SGR-1281"],"award-info":[{"award-number":["2014-SGR-1281"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003030","name":"AGAUR","doi-asserted-by":"crossref","award":["2014-SGR-383"],"award-info":[{"award-number":["2014-SGR-383"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Pl\u00e0 de Recerca de Catalunya, Marat\u00f3 de TV3","award":["100830\/31\/32"],"award-info":[{"award-number":["100830\/31\/32"]}]},{"name":"Fundaci\u00f3 Cellex, Spain"},{"name":"Obra Social La Caixa, Barcelona"},{"name":"Jose Carreras Leukemia Research Institute"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.bbmt.2017.09.001","type":"journal-article","created":{"date-parts":[[2017,9,20]],"date-time":"2017-09-20T11:32:00Z","timestamp":1505907120000},"page":"55-63","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Bone Marrow WT1 Levels in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplasia: Clinically Relevant Time Points and 100 Copies Threshold Value"],"prefix":"10.1016","volume":"24","author":[{"given":"Josep F.","family":"Nomded\u00e9u","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Esquirol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maite","family":"Carricondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Pratcorona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Hoyos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Bussaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Garc\u00eda-Cadenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camino","family":"Estivill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salut","family":"Brunet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5143-4042","authenticated-orcid":false,"given":"Rodrigo","family":"Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Sierra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2017.09.001_bib0010","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1200\/JCO.2015.63.3826","article-title":"Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission?","volume":"34","author":"Araki","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.09.001_bib0015","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/leu.2016.46","article-title":"Pre- and post-transplant quantification of measurable (\u201cminimal\u201d) residual disease via multiparameter flow cytometry in adult acute myeloid leukemia","volume":"30","author":"Zhou","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2017.09.001_bib0020","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1200\/JCO.2014.58.3518","article-title":"Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia","volume":"33","author":"Chen","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.09.001_bib0025","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1182\/blood-2011-08-363291","article-title":"Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia","volume":"119","author":"Buccisano","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.09.001_bib0030","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1038\/leu.2012.120","article-title":"EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes","volume":"26","author":"van Dongen","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2017.09.001_bib0035","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/bjh.14254","article-title":"Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia","volume":"175","author":"Bhatnagar","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2017.09.001_bib0040","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1038\/leu.2013.111","article-title":"Bone marrow WT1 levels at diagnosis, post-induction and post-intensitication in adult de novo AML","volume":"27","author":"Nomded\u00e9u","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2017.09.001_bib0045","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1038\/sj.leu.2404752","article-title":"The Wilms' tumor gene WT1-GFP knock-in mouse reveals the dynamic regulation of WT1 expression in normal and leukemic hematopoiesis","volume":"21","author":"Hosen","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2017.09.001_bib0050","doi-asserted-by":"crossref","first-page":"R196","DOI":"10.1093\/hmg\/ddl196","article-title":"The many facets of the Wilms' tumour gene, WT1","volume":"15","author":"Hohenstein","year":"2006","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.bbmt.2017.09.001_bib0055","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nrc3002","article-title":"Wilms' tumours: about tumour suppressor genes, an oncogene and a chameleon gene","volume":"11","author":"Huff","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bbmt.2017.09.001_bib0060","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1200\/JCO.2009.22.4865","article-title":"Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study","volume":"27","author":"Cilloni","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.09.001_bib0065","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1182\/blood-2003-03-0980","article-title":"Usefulness of quantitative assessment of the WT1 gene transcript as a marker for minimal residual disease detection","volume":"102","author":"Cilloni","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.09.001_bib0070","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.leukres.2009.03.046","article-title":"WT1 monitoring in core binding factor AML: comparison with specific chimeric products","volume":"33","author":"Lasa","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.bbmt.2017.09.001_bib0075","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/j.1365-2141.2008.07132.x","article-title":"Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals","volume":"141","author":"Ommen","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2017.09.001_bib0080","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/j.1365-2141.2004.04952.x","article-title":"WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients\u2014results from a single-centre study","volume":"125","author":"\u00d8stergaard","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2017.09.001_bib0085","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/sj.leu.2403809","article-title":"Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia","volume":"19","author":"Weisser","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2017.09.001_bib0090","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3324\/haematol.12165","article-title":"Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy","volume":"93","author":"Cilloni","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2017.09.001_bib0095","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.bbmt.2014.06.017","article-title":"Wilms' tumor gene 1 transcript levels in leukapheresis of peripheral blood hematopoietic cells predict relapse risk in patients autografted for acute myeloid leukemia","volume":"20","author":"Messina","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.09.001_bib0100","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/bjh.12181","article-title":"Leukaemia relapse after allogeneic transplants for acute myeloid leukaemia: predictive role of WT1 expression","volume":"160","author":"Pozzi","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2017.09.001_bib0105","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00277-013-1733-1","article-title":"Combined use of WT-1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity","volume":"92","author":"Zhao","year":"2013","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bbmt.2017.09.001_bib0110","doi-asserted-by":"crossref","first-page":"e348","DOI":"10.3324\/haematol.2017.167254","article-title":"Combining flow cytometry and WT1 assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia","volume":"102","author":"Guolo","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2017.09.001_bib0115","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00432-014-1832-y","article-title":"Prognostic impact of WT1 expression prior to hematopoietic stem cell transplantation in children with malignant hematological diseases","volume":"141","author":"Woehlecke","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.09.001_bib0120","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1007\/s00432-015-1919-0","article-title":"Detection of relapse after hematopoietic stem cell transplantation in childhood by monitoring of WT1 expression and chimerism","volume":"141","author":"Woehlecke","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.09.001_bib0125","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s40291-015-0147-2","article-title":"WT1 expression in circulating RNA as a minimal residual disease marker for AML patients after stem-cell transplantation","volume":"19","author":"Zhong","year":"2015","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.bbmt.2017.09.001_bib0130","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.bbmt.2016.03.005","article-title":"Wilms' tumor 1 expression and pre-emptive immunotherapy in patients with acute myeloid leukemia undergoing an allogeneic hemopoietic stem cell transplantation","volume":"22","author":"Di Grazia","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.09.001_bib0135","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.leu.2404015","article-title":"Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]","volume":"20","author":"Perea","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2017.09.001_bib0140","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.leukres.2010.05.015","article-title":"Immunophenotype of acute myeloid leukemia with NPM mutations: prognostic impact of the leukemic compartment size","volume":"35","author":"Nomdedeu","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.bbmt.2017.09.001_bib0145","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/sj.bjc.6605462","article-title":"Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines","volume":"102","author":"Mallett","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bbmt.2017.09.001_bib0150","first-page":"774","article-title":"The background level of WT1 expression following alloeneic stem cell transplantation is significantly decreased","volume":"102","author":"Ogawa","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.09.001_bib0155","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1182\/blood-2002-06-1831","article-title":"The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia","volume":"101","author":"Ogawa","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.09.001_bib0160","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/leu.2009.51","article-title":"Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study","volume":"23","author":"Willasch","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2017.09.001_bib0165","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1200\/JCO.2005.03.5303","article-title":"High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia","volume":"24","author":"Lapillonne","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.09.001_bib0170","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s12185-012-1163-1","article-title":"High WT1 mRNA expression after induction chemotherapy and FLT3-ITD have prognostic impact in pediatric acute myeloid leukemia: a study of the Japanese Childhood AML Cooperative Study Group","volume":"96","author":"Shimada","year":"2012","journal-title":"Int J Hematol"},{"key":"10.1016\/j.bbmt.2017.09.001_bib0175","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/bmt.2014.209","article-title":"Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantation","volume":"50","author":"Israyelyan","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.09.001_bib0180","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/bmt.2016.318","article-title":"Impact of Wilms' tumor 1 expression on outcome of patients undergoing allogeneic stem cell transplantation for AML","volume":"52","author":"Dul\u00e9ry","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.09.001_bib0185","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.leukres.2014.11.011","volume":"39","author":"Rossi","year":"2015","journal-title":"Leuk Res"},{"key":"10.1016\/j.bbmt.2017.09.001_bib0190","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.bbmt.2014.11.008","article-title":"Wilms' tumor gene 1 expression as a predictive marker for relapse and survival after hematopoietic stem cell transplantation for myelodysplastic syndromes","volume":"21","author":"Yoon","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.09.001_bib0195","doi-asserted-by":"crossref","unstructured":"Yoon J.H., Kim H.J., Jeon Y.W., et\u00a0al. Outcome of allogeneic hematopoietic stem cell transplantation for cytogenetically normal AML and identification of high-risk subgroup using WT1 expression in association with NPM1 and FLT3-ITD mutations [e-pub ahead of print]. Genes Chromosomes Cancer. doi: 10.1002\/gcc.22260, accessed October 20, 2017.","DOI":"10.1002\/gcc.22260"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108387911730695X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108387911730695X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:00:14Z","timestamp":1761058814000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S108387911730695X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S108387911730695X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2017.09.001","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bone Marrow WT1 Levels in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplasia: Clinically Relevant Time Points and 100 Copies Threshold Value","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2017.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}